10-year lung cancer-specific survival of 80 percent reported in 2006 persisted, with 81 percent survival at 20 years<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Dec. 5, 2023 (HealthDay News) — For an expanded International-Early Lung Cancer Action Program (I-ELCAP) cohort who underwent annual low-dose computed tomography (CT) screening, the 10-year lung cancer-specific survival of 80 percent reported in 2006 has persisted at 20 years, according to a study published online Nov. 7 in Radiology<\/em>.<\/p>\n Claudia I. Henschke, Ph.D., M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues determined the 20-year lung cancer-specific survival of participants diagnosed with first primary lung cancer through annual low-dose CT screening in the I-ELCAP cohort to update the cure rate. Eligible participants were aged 40 years or older and had current or former cigarette use, or had been exposed to secondhand tobacco smoke.<\/p>\n The researchers found that 1,257 (1.4 percent) of the 89,404 I-ELCAP participants were diagnosed with a first primary lung cancer, with a median smoking history of 43.0 pack-years. The median duration of follow-up was 105 months. At pretreatment CT, the frequency of clinical stage 1 was 81 percent (1,017 of 1,257 patients). Both the 10- and 20-year lung cancer-specific survival was 81 percent; for the 181 participants with pathologic T1aN0M0 lung cancer, it was 95 percent.<\/p>\n “Future focus should be on identifying lung cancer even earlier, perhaps during the first 20 doublings rather than the last 20 doublings, as can currently be achieved using low-dose CT,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical and medical technology industries.<\/p>\n Abstract\/Full Text<\/a><\/p>\n